GlobeNewsWire
14 Jun 2026, 18:45 UTC · 22w ago
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
Impact · against what's priced in
The long-term data for PALSONIFY is positive, confirming durable IGF-1 control and tumor stability over two years. While these results reduce clinical risk for the launched product, the impact is moderate as they primarily validate the expected long-term trajectory of the drug's efficacy.
- CRNX+0.40
No priced-in read yet





